Gilead Sciences Inc (GILD)
Gross profit margin
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross profit (ttm) | US$ in thousands | 10,513,000 | 11,791,000 | 12,220,000 | 12,506,000 | 10,372,000 | 11,164,000 | 11,720,000 | 11,666,000 | 14,336,000 | 16,406,000 | 17,436,000 | 18,674,000 | 19,783,000 | 17,966,000 | 17,095,000 | 17,699,000 | 17,444,000 | 17,442,000 | 17,330,000 | 17,067,000 |
| Revenue (ttm) | US$ in thousands | 26,229,000 | 26,516,000 | 26,520,000 | 26,161,000 | 26,413,000 | 26,256,000 | 26,613,000 | 26,496,000 | 26,325,000 | 26,743,000 | 26,144,000 | 25,341,000 | 24,689,000 | 23,147,000 | 22,174,000 | 22,716,000 | 22,449,000 | 22,365,000 | 22,357,000 | 22,320,000 |
| Gross profit margin | 40.08% | 44.47% | 46.08% | 47.80% | 39.27% | 42.52% | 44.04% | 44.03% | 54.46% | 61.35% | 66.69% | 73.69% | 80.13% | 77.62% | 77.09% | 77.91% | 77.71% | 77.99% | 77.51% | 76.47% |
December 31, 2023 calculation
Gross profit margin = Gross profit (ttm) ÷ Revenue (ttm)
= $10,513,000K ÷ $26,229,000K
= 40.08%
Gilead Sciences, Inc.'s gross profit margins have shown variability over the past eight quarters, ranging from a high of 79.42% in Q2 2023 to a low of 74.62% in Q3 2022. The gross profit margin measures the percentage of revenue retained by the company after accounting for the cost of goods sold.
Overall, Gilead has maintained relatively strong gross profit margins, with an average of approximately 77.45% over the eight quarters analyzed. The fluctuations in gross profit margins can be influenced by various factors, such as changes in production costs, pricing strategies, or product mix.
The increasing trend from Q3 2022 to Q2 2023 indicates improvements in managing production costs or pricing strategies. However, the decline in Q4 2023 compared to the previous quarter may suggest potential challenges or changes impacting the company's cost structure and revenue generation.
It would be insightful to delve deeper into the specific reasons behind these fluctuations in order to assess the overall financial health and efficiency of Gilead Sciences, Inc.
Peer comparison
Dec 31, 2023